Browsing by author "Yarnold, John"
Now showing items 21-32 of 32
-
Late normal tissue effects in the arm and shoulder following lymphatic radiotherapy: Results from the UK START (Standardisation of Breast Radiotherapy) trials.
Haviland, JS; Mannino, M; Griffin, C; Porta, N; Sydenham, M; et al. (ELSEVIER IRELAND LTD, 2018-01-01)BACKGROUND AND PURPOSE: Adjuvant lymphatic radiotherapy (LNRT) is recommended for selected axillary node positive women with early breast cancer. We investigated whether hypofractionated LNRT is safe combined with ... -
Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG), (ELSEVIER SCIENCE INC, 2018-01-01)BACKGROUND: Neoadjuvant chemotherapy (NACT) for early breast cancer can make breast-conserving surgery more feasible and might be more likely to eradicate micrometastatic disease than might the same chemotherapy given after ... -
Partial breast radiotherapy after breast conservation surgery for early breast cancer: 5-year outcomes from the IMPORT LOW (CRUK/06/003) phase III randomised controlled trial
Coles, C; Griffin, C; Kirby, A; Titley, J; Agrawal, R; et al. (2017-05-15) -
Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial.
Coles, CE; Griffin, CL; Kirby, AM; Titley, J; Agrawal, RK; et al. (ELSEVIER SCIENCE INC, 2017-09-09)BACKGROUND: Local cancer relapse risk after breast conservation surgery followed by radiotherapy has fallen sharply in many countries, and is influenced by patient age and clinicopathological factors. We hypothesise that ... -
Patient-Reported Outcomes Over 5 Years After Whole- or Partial-Breast Radiotherapy: Longitudinal Analysis of the IMPORT LOW (CRUK/06/003) Phase III Randomized Controlled Trial.
Bhattacharya, IS; Haviland, JS; Kirby, AM; Kirwan, CC; Hopwood, P; et al. (2019-02)Purpose IMPORT LOW demonstrated noninferiority of partial-breast and reduced-dose radiotherapy versus whole-breast radiotherapy for local relapse and similar or reduced toxicity at 5 years. Comprehensive patient-reported ... -
Patient-Reported Outcomes Over 5 Years After Whole- or Partial-Breast Radiotherapy: Longitudinal Analysis of the IMPORT LOW (CRUK/06/003) Phase III Randomized Controlled Trial.
Bhattacharya, IS; Haviland, JS; Kirby, AM; Kirwan, CC; Hopwood, P; et al. (AMER SOC CLINICAL ONCOLOGY, 2019-02-01)PURPOSE: IMPORT LOW demonstrated noninferiority of partial-breast and reduced-dose radiotherapy versus whole-breast radiotherapy for local relapse and similar or reduced toxicity at 5 years. Comprehensive patient-reported ... -
Prolongation of overall treatment time as a cause of treatment failure in early breast cancer: An analysis of the UK START (Standardisation of Breast Radiotherapy) trials of radiotherapy fractionation.
Haviland, JS; Bentzen, SM; Bliss, JM; Yarnold, JR; START Trial Management Group, (ELSEVIER IRELAND LTD, 2016-08-29)BACKGROUND: Tests of tumour treatment time effect in patients prescribed post-operative radiotherapy for early breast cancer have focussed on time to start of radiotherapy rather than overall treatment time. The START ... -
Randomised single centre double-blind placebo controlled phase II trial of Tocovid SupraBio in combination with pentoxifylline in patients suffering long-term gastrointestinal adverse effects of radiotherapy for pelvic cancer: The PPALM study.
Andreyev, HJN; Matthews, J; Adams, C; Gothard, L; Lucy, C; et al. (ELSEVIER IRELAND LTD, 2022-03-01)BACKGROUND: Preclinical data suggest that combined gamma-tocotrienol with pentoxifylline ameliorates radiotherapy-induced gastrointestinal damage. AIM: To test whether gastrointestinal symptoms arising after radiotherapy, ... -
Simulation of a radiobiology facility for the Centre for the Clinical Application of Particles.
Kurup, A; Pasternak, J; Taylor, R; Murgatroyd, L; Ettlinger, O; et al. (ELSEVIER SCI LTD, 2019-09-01)The Centre for the Clinical Application of Particles' Laser-hybrid Accelerator for Radiobiological Applications (LhARA) facility is being studied and requires simulation of novel accelerator components (such as the Gabor ... -
Ten-Year Results of FAST: A Randomized Controlled Trial of 5-Fraction Whole-Breast Radiotherapy for Early Breast Cancer.
Brunt, AM; Haviland, JS; Sydenham, M; Agrawal, RK; Algurafi, H; et al. (AMER SOC CLINICAL ONCOLOGY, 2020-10-01)PURPOSE: Previous studies of hypofractionated adjuvant whole-breast radiotherapy for early breast cancer established a 15- or 16-fraction (fr) regimen as standard. The FAST Trial (CRUKE/04/015) evaluated normal tissue ... -
The UK HeartSpare Study (Stage II): Multicentre Evaluation of a Voluntary Breath-hold Technique in Patients Receiving Breast Radiotherapy.
Bartlett, FR; Donovan, EM; McNair, HA; Corsini, LA; Colgan, RM; et al. (ELSEVIER SCIENCE LONDON, 2017-03-01)AIMS: To evaluate the feasibility and heart-sparing ability of the voluntary breath-hold (VBH) technique in a multicentre setting. MATERIALS AND METHODS: Patients were recruited from 10 UK centres. Following surgery for ... -
TP53 modulates radiotherapy fraction size sensitivity in normal and malignant cells.
Anbalagan, S; Ström, C; Downs, JA; Jeggo, PA; McBay, D; et al. (NATURE PORTFOLIO, 2021-03-29)Recent clinical trials in breast and prostate cancer have established that fewer, larger daily doses (fractions) of radiotherapy are safe and effective, but these do not represent personalised dosing on a patient-by-patient ...